The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions

Background/Objectives: Cimicifuga racemosa (CR), a botanical widely used for postmenopausal osteoporosis (PMOP), concurrently functionally engages cannabinoid receptor 2 (CB2R) and estrogen receptor α (ERα), but the downstream signaling pathways remain to be fully elucidated. This study aimed to identify CR-derived constituents with dual binding potential for CB2R and ERα and to elucidate their mechanism of action in osteoclastogenesis. Methods: A structure-informed pipeline integrating machine learning classification, hierarchical molecular docking, and molecular dynamics simulations was established to screen for CB2R modulators. Candidate compounds were validated using relative luminescence assays, cyclic adenosine monophosphate measurements, ERα concentration assays, cellular thermal shift assays, and co-immunoprecipitation analyses. Transcriptomic profiling coupled with Gene Ontology slim enrichment was performed to delineate CB2R and ERα regulatory networks in osteoclasts (OCs). Anti-osteoclastogenic effects and downstream mechanisms were investigated in RAW264.7-derived OCs, with pharmacological inhibition of CB2R and ERα confirming target specificity. Results: Among 431 compounds, cimigenol-3-one was identified as a CB2R agonist-like compound that increased ERα protein levels and required ERα for its anti-osteoclastogenic effects. It inhibited RANKL-induced osteoclastogenesis, disrupted F-actin rings, and downregulated key bone-resorptive genes. Mechanistically, it disrupted lysosomal function (reduced Lis1, Rab7, and Lamp2) and suppressed autophagic flux (inhibited Beclin-1 and ATGs). Genetic knockdown or pharmacological blockade of CB2R and ERα reversed these effects, confirming that coordinated receptor activation disrupts lysosomal homeostasis and autophagy. Conclusions: Cimigenol-3-one, identified from CR via AI-assisted screening, acted as the CB2R modulator with concurrent upregulation of ERα to suppress osteoclast bone resorption by disrupting lysosomal function and autophagic flux.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-18
DOI
https://doi.org/10.3390/ph19111838
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions

Luping Qin, Gao-ce Chen, Gang Cheng, Mengyi Shan et al.
2 links
Pharmaceuticals
Bone Metabolism and Diseases
article

The CB2R Modulator with Concurrent Upregulation of ERα from Cimicifuga racemosa Suppresses Bone Resorption of Osteoclasts Through the Inhibition of Autophagy and Lysosome Functions

Luping Qin, Gao-ce Chen, Gang Cheng, Mengyi Shan, Yan Yu-Yuan, Sijing Hu, Zi-le Song, Ting Han, Qiao-Yan Zhang
article en

Abstract

Background/Objectives: Cimicifuga racemosa (CR), a botanical widely used for postmenopausal osteoporosis (PMOP), concurrently functionally engages cannabinoid receptor 2 (CB2R) and estrogen receptor α (ERα), but the downstream signaling pathways remain to be fully elucidated. This study aimed to identify CR-derived constituents with dual binding potential for CB2R and ERα and to elucidate their mechanism of action in osteoclastogenesis. Methods: A structure-informed pipeline integrating machine learning classification, hierarchical molecular docking, and molecular dynamics simulations was established to screen for CB2R modulators. Candidate compounds were validated using relative luminescence assays, cyclic adenosine monophosphate measurements, ERα concentration assays, cellular thermal shift assays, and co-immunoprecipitation analyses. Transcriptomic profiling coupled with Gene Ontology slim enrichment was performed to delineate CB2R and ERα regulatory networks in osteoclasts (OCs). Anti-osteoclastogenic effects and downstream mechanisms were investigated in RAW264.7-derived OCs, with pharmacological inhibition of CB2R and ERα confirming target specificity. Results: Among 431 compounds, cimigenol-3-one was identified as a CB2R agonist-like compound that increased ERα protein levels and required ERα for its anti-osteoclastogenic effects. It inhibited RANKL-induced osteoclastogenesis, disrupted F-actin rings, and downregulated key bone-resorptive genes. Mechanistically, it disrupted lysosomal function (reduced Lis1, Rab7, and Lamp2) and suppressed autophagic flux (inhibited Beclin-1 and ATGs). Genetic knockdown or pharmacological blockade of CB2R and ERα reversed these effects, confirming that coordinated receptor activation disrupts lysosomal homeostasis and autophagy. Conclusions: Cimigenol-3-one, identified from CR via AI-assisted screening, acted as the CB2R modulator with concurrent upregulation of ERα to suppress osteoclast bone resorption by disrupting lysosomal function and autophagic flux.

PharmaceuticalsVol. 19(11)
Zhejiang Chinese Medical University (CN), Second Military Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Bone Metabolism and Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon